Rockies Chapter Meeting Please join your cardiology colleagues at the ACC Rockies Chapter Meeting in Park City, Utah for updates on ACC affairs, the potential new CV Board, and clinical topics such as Genetic and Sports EP, plus a discussion on the growing role of obesity medications in heart failure, and the first-ever Cardiology State-of-the-State report. There will be many opportunities for networking, as well!. For more information and to register, please visit: ACC Rockies Chapter Meeting 2025

ACC Live Courses
For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings

RSS Latest in Cardiology from ACC.org

  • Rhythm Control May Improve Moderate-Severe/Severe Secondary TR
    Successful rhythm control of atrial fibrillation (AFib) was associated with improved secondary tricuspid regurgitation (STR) in patients with moderate-severe or severe STR, according to research published April 23 in JACC: Cardiovascular Imaging.
  • Poor Visual Acuity Associated With Cardiovascular, All-Cause Mortality Risk
    In a nationwide cohort of more than 2.5 million Chinese adults aged 65 years or older, visual acuity (VA) impairment was highly prevalent and independently associated with increased risk of mortality from any cause and from cardiovascular disease, according to a large-scale study published April 15 in JACC.
  • Hypertension Risk From Low-Level PM Exposure
    Long-term exposure to fine particulate matter ≤2.5 μm in diameter (PM2.5), which is below current regulatory thresholds in the U.S., may contribute to increased hypertension risk, according to a national cohort study published April 15 in JACC.
  • ORBITA Analysis: Microvascular Resistance Impacts PCI Benefit
    Patients with lower microvascular resistance (MVR) saw greater placebo-controlled benefit from PCI, according to a retrospective analysis of the ORBITA trial published April 29 in JACC: Cardiovascular Interventions.
  • BP Reduction Brings Comparable CV Benefits in CKD
    Patients with chronic kidney disease (CKD) enjoyed the same reduction in cardiovascular risk from lowering systolic blood pressure (SBP) as those without CKD, and this finding held across all CKD stages, BP thresholds, proteinuria status and antihypertensive class, according to research published April 25 in The Lancet.